Alzheimer’s disease (AD) is a progressive neurodegenerative disease characterized by memory loss, cognitive impairment, and functional decline. The cause of AD is unknown, but it appears to be multifactorial, with most research aimed at the Aβ peptides and tau proteins. The risk of developing AD is believed to be determined by a combination of genetic, metabolic, behavioral, and environmental factors.

alzheimers disease pipeline

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

AD clinical trials show moderate enrolment efficiencies. The average number of subjects recruited in Phase II/III and Phase III trials was more than 900 patients and 700 patients, respectively. Despite the large difference in accruals, trials in all phases had moderate enrolment efficiency based on both the number of subjects planned and the number of subjects enrolled.

GlobalData’s report ‘Alzheimer’s Disease (AD): Competitive Landscape to 2026’ provides an assessment of the pipeline, clinical, and commercial landscape of AD. Overall, GlobalData expects new drug approvals to drive AD market growth over the next decade to 2026.

Alessio Brunello, MSc, Neurology analyst at GlobalData comments:

“The AD pipeline features 657 drugs across all stages of development. Out of these, only 3.2% of drugs are in late stage development, highlighting the high attrition rate in this field.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Report highlights include:

  • Pipeline Assessment – regional breakdown, promising late-stage products, early-stage pipeline by molecule type
  • Clinical Trials Assessment – trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics
  • Commercial Assessment – leading marketed products, current and future players
  • Competitive Landscape Analysis – key market events (2016–2026)

GlobalData’s report helps you to develop and plan in-licensing and out-licensing strategies through a review of pipeline products and technologies, and identify companies with the most robust pipeline. The report also allows you to gain an understanding of key trends, innovative products and technologies, market segments, and companies that are likely to impact the global AD market in future.

If you would like any more information on this report, please visit the GlobalData Report Store.